Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS)

Q: What does CUSIP 00461U105 represent in this 13F holders report?

CUSIP 00461U105 is the security identifier for ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share in Q4 2021?

133 institutional investors reported ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share for Q4 2021. Use the holders table for investor-level position and value details.

CUSIP: 00461U105

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class: Equity / Common Stock, $0.00001 par value per share
Shares outstanding: 121,058,810
Total 13F shares: 56,045,310
Share change: -1,869,974
Total reported value: $814,890,981
Put/Call ratio: 0%
Price per share: $14.54
Number of holders: 133
Value change: -$39,784,690
Number of buys: 72
Number of sells: 56

Quarterly Holders Quick Answers

What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2022
Previous quarter: Q3 2021

Recent filing periods for CUSIP 00461U105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	4.5%	5,420,453	$97,568,000	—	30 Sep 2021	13F
VR Adviser, LLC	13F	Company	3.8%	4,563,962	$82,151,000	—	30 Sep 2021	13F
Rock Springs Capital Management LP	13F	Company	3.1%	3,803,232	$68,458,000	—	30 Sep 2021	13F
BlackRock Finance, Inc.	13F	Company	3.1%	3,788,417	$68,192,000	—	30 Sep 2021	13F
Foresite Capital Management IV, LLC	13F	Company	2.8%	3,399,034	$61,183,000	—	30 Sep 2021	13F
VANGUARD GROUP INC	13F	Company	2.2%	2,678,940	$48,221,000	—	30 Sep 2021	13F
Commodore Capital LP	13F	Company	1.8%	2,190,291	$39,425,000	—	30 Sep 2021	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.7%	2,020,878	$36,376,000	—	30 Sep 2021	13F
Holocene Advisors, LP	13F	Company	1.6%	1,955,605	$35,201,000	—	30 Sep 2021	13F
Foresite Capital Management III, LLC	13F 3/4/5	Company · 10%+ Owner	1.6%	1,954,904	$35,188,000	—	30 Sep 2021	13F 3/4/5
FMR LLC	13F	Company	1.3%	1,583,089	$28,496,000	—	30 Sep 2021	13F
Cormorant Asset Management, LP	13F	Company	1.2%	1,500,000	$27,000,000	—	30 Sep 2021	13F
BVF INC/IL	13F	Company	1.1%	1,373,044	$24,715,000	—	30 Sep 2021	13F
Parkman Healthcare Partners LLC	13F	Company	1.1%	1,306,460	$23,516,000	—	30 Sep 2021	13F
Foresite Capital Management V, LLC	13F	Company	1%	1,258,243	$22,648,000	—	30 Sep 2021	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.89%	1,075,366	$19,357,000	—	30 Sep 2021	13F
CITADEL ADVISORS LLC	13F	Company	0.88%	1,063,617	$19,145,000	—	30 Sep 2021	13F
STATE STREET CORP	13F	Company	0.87%	1,058,164	$19,047,000	—	30 Sep 2021	13F
Vivo Capital, LLC	13F	Company	0.78%	940,754	$16,934,000	—	30 Sep 2021	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.66%	795,826	$14,324,000	—	30 Sep 2021	13F
Samsara BioCapital, LLC	13F	Company	0.66%	794,171	$14,295,000	—	30 Sep 2021	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.65%	781,236	$14,062,000	—	30 Sep 2021	13F
ORBIMED ADVISORS LLC	13F	Company	0.54%	651,783	$11,732,000	—	30 Sep 2021	13F
Aisling Capital Management LP	13F	Company	0.52%	634,455	$11,420,000	—	30 Sep 2021	13F
Woodline Partners LP	13F	Company	0.49%	594,768	$10,706,000	—	30 Sep 2021	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.42%	512,875	$9,231,000	—	30 Sep 2021	13F
NORTHERN TRUST CORP	13F	Company	0.41%	501,633	$9,030,000	—	30 Sep 2021	13F
GREAT POINT PARTNERS LLC	13F	Company	0.41%	500,000	$9,000,000	—	30 Sep 2021	13F
Laurion Capital Management LP	13F	Company	0.41%	492,500	$8,865,000	—	30 Sep 2021	13F
Assenagon Asset Management S.A.	13F	Company	0.39%	473,365	$8,521,000	—	30 Sep 2021	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.36%	441,094	$7,939,000	—	30 Sep 2021	13F
Invesco Ltd.	13F	Company	0.36%	438,802	$7,898,000	—	30 Sep 2021	13F
FRAZIER MANAGEMENT LLC	13F	Company	0.34%	408,329	$7,350,000	—	30 Sep 2021	13F
Point72 Asset Management, L.P.	13F	Company	0.32%	391,300	$7,043,000	—	30 Sep 2021	13F
Affinity Asset Advisors, LLC	13F	Company	0.29%	350,000	$6,300,000	—	30 Sep 2021	13F
DEUTSCHE BANK AG\	13F	Company	0.27%	322,439	$5,804,000	—	30 Sep 2021	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.27%	321,191	$5,781,000	—	30 Sep 2021	13F
Ghost Tree Capital, LLC	13F	Company	0.23%	275,000	$4,950,000	—	30 Sep 2021	13F
Nuveen Asset Management, LLC	13F	Company	0.22%	272,090	$4,941,000	—	30 Sep 2021	13F
Asymmetry Capital Management, L.P.	13F	Company	0.2%	241,701	$4,351,000	—	30 Sep 2021	13F
Integral Health Asset Management, LLC	13F	Company	0.15%	185,000	$3,330,000	—	30 Sep 2021	13F
Bank of New York Mellon Corp	13F	Company	0.15%	182,245	$3,281,000	—	30 Sep 2021	13F
J. Goldman & Co LP	13F	Company	0.15%	177,740	$3,199,000	—	30 Sep 2021	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.14%	173,327	$3,120,000	—	30 Sep 2021	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.13%	161,843	$2,913,000	—	30 Sep 2021	13F
Darwin Global Management, Ltd.	13F	Company	0.13%	159,393	$2,869,000	—	30 Sep 2021	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.12%	140,839	$2,535,000	—	30 Sep 2021	13F
Jetstream Capital LLC	13F	Company	0.12%	140,000	$2,520,000	—	30 Sep 2021	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.1%	126,916	$2,285,000	—	30 Sep 2021	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.1%	120,549	$2,170,000	—	30 Sep 2021	13F

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS) as of Q4 2021

As of 31 Dec 2021, Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS) was held by 133 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 56,045,310 shares. The largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, VR Adviser, LLC, BlackRock Inc., Rock Springs Capital Management LP, Foresite Capital Management IV, LLC, VANGUARD GROUP INC, COMMODORE CAPITAL LP, Holocene Advisors, LP, BVF INC/IL, and RENAISSANCE TECHNOLOGIES LLC. This page lists 133 institutional shareholders reporting positions in this security for the Q4 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2021 vs Q3 2021 Across Filers

Q3 2021 holders

126

Q4 2021 holders

133

Holder diff

Investor	Q3 2021 Shares	Q4 2021 Shares	Share Diff	Share Chg %	Q3 2021 Value $	Q4 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.